Pivotal STELLAR-303 Trial Looks to Validate Preliminary Findings Following the positive preclinical and earlyphase findings displayed by XL092, investigators are initiating the phase 3, global, open-label STELLAR-303 trial (NCT05425940).4 Exelixis, the developer of XL092, cited promising outcomes ob...
STELLAR-303 enrollment is ongoing in the US, Europe, and Asia-Pacific region.Clinical trial information: NCT05425940.Anwaar SaeedDepartment of Medical Oncology, University of Pittsburgh, Pittsburgh, PAJosep TaberneroVall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-...
You’ll first need to accept the request “Recruit Passcode Specialists” from the Bulletin Board in Xion, then you’ll need to collect all 6 Chapter of Trial documents. Afterward, you can go to the gate in the wrecked ship and put in the code βθαλδζ to open it and take what...
Nachr., 303, 251–261. ADS Google Scholar Gizon, L., 2002, “Prospects for detecting stellar activity through asteroseismology”, Astron. Nachr., 323, 251–253. ADS Google Scholar Gizon, L., Solanki, S.K., 2004, “Measuring Stellar Differential rotation with asteroseismology”, Solar...
We read every piece of feedback, and take your input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly Cancel Create saved search Sign in Sign up Reseting focus {...
STELLAR-303 is a phase 3 study evaluating the efficacy and safety of XL092 + atezolizumab versus regorafenib in patients with previously treated RASwt or RASmut mCRC. Methods: STELLAR-303 (XL092-303; NCT05425940) is a global, open-label, randomized phase 3 study. Eligible patients are 鈮 ...